The 20th Anniversary of Medicilon's Establishment-Wish of KOLs

In the past 20 years, the development of Medicilon witnessed the global advancement of the pharmaceutical industry. Medicilon played a significant role in promoting the high-quality development of the Chinese pharmaceutical industry. Medicilon has become an important force in the pharmaceutical industry chain and showcases the vitality of the Chinese pharmaceutical industry. 

As one of the early CRO companies in China, Medicilon has gradually grown from a small company with only a dozen employees to the first Zhangjiang biopharmaceutical enterprise being successfully listed on the STAR Market. It is also the first CRO company listed on the STAR Market.

The model of CRO has greatly facilitated the development of domestic pharmaceutical companies in China, which reduced the cost of R&D and improved the efficiency of R&D for pharmaceutical companies. Even in basic scientific research, we also rely on the help of CRO. Medicilon has established a comprehensive technical chain covering preclinical drug development for both traditional small molecule drugs andtechnological new drugs.

Medicilon is particularly renowned for its expertise in small molecule synthesis, preclinical animal safety evaluation, and animal models. Medicilon has a strong team with excellent capabilities, providing better services to clients. We are grateful for the cooperation with Medicilon over the past 20 years.

From 2004.2.2 to 2024.2.2, every collaboration begins with a dream of new drugs.
Every trust is worth our full dedication.
For two decades, Medicilon has remained steadfast and innovative.
Medicilon is fortunate to have the support and love of over 2000 global clients, which drives us to constantly innovate, surpass ourselves, and empower others.
We walk hand in hand, shoulder to shoulder.

Medicilon is grateful for the love and support from all of you in pharmaceutical industry.